Anand Muthusamy
@anandmuthusamy.bsky.social
Science & adventure. Fellow @ Convergent Research. PhD @ Caltech: protein engineering + neuroscience. Prev: chem bio & biotech venture capital. anandmuthusamy.com
Photo gallery source: www.barnsdall.org/hollyhock-ho...
September 12, 2025 at 3:34 PM
Photo gallery source: www.barnsdall.org/hollyhock-ho...
Future posts will be more science/tech oriented. But I had to talk about this work for its creativity par excellence. You know the increasingly popular saying “never trust a thought you have indoors” - Hollyhock gives us an exception.
September 12, 2025 at 3:33 PM
Future posts will be more science/tech oriented. But I had to talk about this work for its creativity par excellence. You know the increasingly popular saying “never trust a thought you have indoors” - Hollyhock gives us an exception.
The full paper will be open access shortly, but please DM for a copy. academic.oup.com/ntr/advance-...
Continuous Nicotine Monitors for Personal Nicotine Pharmacokinetics: A Receptor-Aware Research Agenda
Abstract. A minimally invasive “continuous nicotine monitor” (CNM) would resolve the dynamic nicotine concentration, [nicotine]t, faced by high-sensitivity
academic.oup.com
June 17, 2025 at 8:30 PM
The full paper will be open access shortly, but please DM for a copy. academic.oup.com/ntr/advance-...
Awesome work by all our co-authors over the years - special shoutout to the lead, Aaron Nichols, Neal Benowitz who studies PK in humans and gave a clinical grounding, and Henry Lester who had led the way in thinking about nicotine receptors and drug PK
June 17, 2025 at 8:30 PM
Awesome work by all our co-authors over the years - special shoutout to the lead, Aaron Nichols, Neal Benowitz who studies PK in humans and gave a clinical grounding, and Henry Lester who had led the way in thinking about nicotine receptors and drug PK
Measuring drug PK in large populations, especially in daily life, is challenging with existing lab methods. We outline the requirements for a new device to measure nicotine in situ, and we simulate the measurement feasibility in this paper.
June 17, 2025 at 8:30 PM
Measuring drug PK in large populations, especially in daily life, is challenging with existing lab methods. We outline the requirements for a new device to measure nicotine in situ, and we simulate the measurement feasibility in this paper.
What routines or environmental cues during the bolus or prolonged phase drive addiction? What regimens would help people taper off?
Likewise, all these questions can be applied to smoking cessation drugs in development: do they hit the right PK for the intended behavior change?
Likewise, all these questions can be applied to smoking cessation drugs in development: do they hit the right PK for the intended behavior change?
June 17, 2025 at 8:30 PM
What routines or environmental cues during the bolus or prolonged phase drive addiction? What regimens would help people taper off?
Likewise, all these questions can be applied to smoking cessation drugs in development: do they hit the right PK for the intended behavior change?
Likewise, all these questions can be applied to smoking cessation drugs in development: do they hit the right PK for the intended behavior change?
Several research directions would benefit from more real-world human data:
Do “low nicotine” or oral pouch products blunt the bolus that drives addiction?
What genotype or lifestyle factors explain the variance in PK across a population or within an individual over time?
Do “low nicotine” or oral pouch products blunt the bolus that drives addiction?
What genotype or lifestyle factors explain the variance in PK across a population or within an individual over time?
June 17, 2025 at 8:30 PM
Several research directions would benefit from more real-world human data:
Do “low nicotine” or oral pouch products blunt the bolus that drives addiction?
What genotype or lifestyle factors explain the variance in PK across a population or within an individual over time?
Do “low nicotine” or oral pouch products blunt the bolus that drives addiction?
What genotype or lifestyle factors explain the variance in PK across a population or within an individual over time?
Nicotine is thought to enhance the reward value of other stimuli alongside - again, these have to be lined up in time to build routines around use (e.g., smoke break with coffee).
June 17, 2025 at 8:30 PM
Nicotine is thought to enhance the reward value of other stimuli alongside - again, these have to be lined up in time to build routines around use (e.g., smoke break with coffee).
Nicotine addiction is highly schedule- and dose-dependent: cigarettes and vapes tap into the lungs for quick (< 10 min), large bolus necessary for reinforcement with a related sense of well-being, stress relief, or cognitive boost, followed by a prolonged phase that suppresses withdrawal symptoms.
June 17, 2025 at 8:30 PM
Nicotine addiction is highly schedule- and dose-dependent: cigarettes and vapes tap into the lungs for quick (< 10 min), large bolus necessary for reinforcement with a related sense of well-being, stress relief, or cognitive boost, followed by a prolonged phase that suppresses withdrawal symptoms.
